{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Meer R"],"funding":["Dutch Research Council (NWO)"],"pagination":["10"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12801761"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["<h4>Background</h4>Heart failure and peripheral artery disease (PAD) are the two most common cardiovascular diseases (CVD) in individuals with type 2 diabetes mellitus (T2DM). The T<sub>50</sub> calciprotein crystallization test measures the transformation of calciprotein particles type 1 (CPP1) into CPP2 in vitro and has been introduced as a low-cost biomarker for arterial calcification and CVD risk. We aimed to investigate the association between T<sub>50</sub> and (1) heart failure with preserved ejection fraction (HFpEF), (2) ankle-brachial index (ABI) as measure of PAD, (3) pulse wave velocity (PWV) as measure of central arterial stiffness and (4) arterial calcification in individuals with T2DM.<h4>Methods</h4>Cross-sectional data was used of 771 individuals with T2DM (64% men, 67 [63"],"journal":["Cardiovascular diabetology"],"pubmed_title":["Calciprotein crystallization time (T&lt;sub&gt;50&lt;/sub&gt;) and its association with surrogate cardiovascular disease risk markers in individuals with type 2 diabetes mellitus: the cross-sectional EARLY-HFpEF study."],"pmcid":["PMC12801761"],"funding_grant_id":["91718304"],"pubmed_authors":["Hoek AG","Meer R","Pasch A","Vervloet MG","Doesburg T","Beulens JWJ","Dal Canto E","de Jong PA","Elders PJM"],"additional_accession":[]},"is_claimable":false,"name":"Calciprotein crystallization time (T&lt;sub&gt;50&lt;/sub&gt;) and its association with surrogate cardiovascular disease risk markers in individuals with type 2 diabetes mellitus: the cross-sectional EARLY-HFpEF study.","description":"<h4>Background</h4>Heart failure and peripheral artery disease (PAD) are the two most common cardiovascular diseases (CVD) in individuals with type 2 diabetes mellitus (T2DM). The T<sub>50</sub> calciprotein crystallization test measures the transformation of calciprotein particles type 1 (CPP1) into CPP2 in vitro and has been introduced as a low-cost biomarker for arterial calcification and CVD risk. We aimed to investigate the association between T<sub>50</sub> and (1) heart failure with preserved ejection fraction (HFpEF), (2) ankle-brachial index (ABI) as measure of PAD, (3) pulse wave velocity (PWV) as measure of central arterial stiffness and (4) arterial calcification in individuals with T2DM.<h4>Methods</h4>Cross-sectional data was used of 771 individuals with T2DM (64% men, 67 [63","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T14:57:31.133Z","creation":"2026-06-01T03:07:47.619Z"},"accession":"S-EPMC12801761","cross_references":{"pubmed":["41372769"],"doi":["10.1186/s12933-025-03016-9"]}}